Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients

被引:25
作者
Demiraslan, Hayati [1 ]
Sevim, Mustafa [2 ]
Pala, Cigdem [3 ]
Durmaz, Suleyman [4 ]
Berk, Veli [5 ]
Kaynar, Leylagul [3 ]
Metan, Gokhan [1 ]
机构
[1] Erciyes Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Kayseri, Turkey
[2] Erciyes Univ, Fac Med, Dept Internal Med, Kayseri, Turkey
[3] Erciyes Univ, Fac Med, Dept Hematol, Kayseri, Turkey
[4] Erciyes Univ, Fac Med, Dept Microbiol, Kayseri, Turkey
[5] Erciyes Univ, Fac Med, Dept Oncol, Kayseri, Turkey
关键词
Stenotrophomonas maltophilia; Hematologic malignancy; Solid tumor; Cancer; Severe sepsis; Neutropenia; Mortality; ANTIMICROBIAL SURVEILLANCE PROGRAM; CENTRAL VENOUS CATHETER; BACTEREMIA; DEFINITIONS; THERAPY; GUIDELINES; MANAGEMENT; RESISTANCE; PATHOGEN; PATTERNS;
D O I
10.1007/s12185-013-1296-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stenotrophomonas maltophilia infection is of concern in patients with cancer. Antibiotics active against S. maltophilia are rarely used in the treatment of febrile neutropenia, making it important to identify the factors influencing mortality in cancer patients with S. maltophilia infection. The objective of this study was to analyze the clinical characteristics and outcomes of cancer and hemopathic patients with S. maltophilia infection and assess the factors influencing the mortality. The microbiology laboratory records of Erciyes University, Faculty of Medicine Hospital were reviewed to retrospectively identify patients with S. maltophilia infection between January 2007 and June 2011. A total of 38 patients (25 male, 13 female) were eligible for the study. The median age of the patients was 53 years. The underlying disease was hematological malignancy and disorders in 76.3 % (29 cases), solid tumors in 15.8 % (six cases), aplastic anemia in 7.9 % (three cases), while 18.4 % (seven cases) were hematopoietic stem cell transplantation (HSCT) recipients. An indwelling central venous catheter was used in 32 cases (84.2 %). Twenty-seven patients (71.1 %) were neutropenic at the onset of infection. Nine patients (23.7 %) were receiving corticosteroid therapy. The overall 14-day mortality rate was 50 %. Three of the patients received empirical antibacterial treatment, and three HSCT recipients received trimethoprim-sulfamethoxazole prophylaxis, which is active against S. maltophilia. Severe sepsis (OR 13.24, 95 % confidence interval (CI) 1.62-108.57) and the duration of the treatment (OR 0.73, 95 % CI 0.60-0.90) were related to death based on logistic regression analysis findings. In immunocompromised hematology-oncology patients with severe sepsis, S. maltophilia should be considered as a possible cause of infection, and should be given effective empirical antibiotic treatment immediately; the antimicrobial spectrum may be narrowed according to results of antibiotic susceptibility test.
引用
收藏
页码:414 / 420
页数:7
相关论文
共 37 条
[1]   Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004 [J].
Aisenberg, G. ;
Rolston, K. V. ;
Dickey, B. F. ;
Kontoyiannis, D. P. ;
Raad, I. I. ;
Safdar, A. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (01) :13-20
[2]   Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients:: A case-control study [J].
Apisarnthanarak, A ;
Mayfield, JL ;
Garison, T ;
McLendon, PM ;
DiPersio, JF ;
Fraser, VJ ;
Polish, LB .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2003, 24 (04) :269-274
[3]   Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009 [J].
Araoka, H. ;
Baba, M. ;
Yoneyama, A. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (05) :605-608
[4]   Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia [J].
Bliziotis, Ioannis A. ;
Petrosillo, Nicola ;
Michalopoulos, Argyris ;
Samonis, George ;
Falagas, Matthew E. .
PLOS ONE, 2011, 6 (10)
[5]   Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients [J].
Boktour, M ;
Hanna, H ;
Ansari, S ;
Bahna, B ;
Hachem, R ;
Tarrand, J ;
Rolston, K ;
Safdar, A ;
Raad, I .
CANCER, 2006, 106 (09) :1967-1973
[6]   A SIMPLE METHOD FOR SELECTIVE ISOLATION OF STENOTROPHOMONAS-MALTOPHILIA FROM ENVIRONMENTAL-SAMPLES [J].
BOLLET, C ;
DAVINREGLI, A ;
DEMICCO, P .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1995, 61 (04) :1653-1654
[7]   Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen [J].
Brooke, Joanna S. .
CLINICAL MICROBIOLOGY REVIEWS, 2012, 25 (01) :2-41
[8]   Predictors of catheter-related gram-negative bacilli bacteraemia among cancer patients [J].
Cairo, J. ;
Hachem, R. ;
Rangaraj, G. ;
Granwehr, B. ;
Raad, I. .
CLINICAL MICROBIOLOGY AND INFECTION, 2011, 17 (11) :1711-1716
[9]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[10]   Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].
De Pauw, Ben ;
Walsh, Thomas J. ;
Donnelly, J. Peter ;
Stevens, David A. ;
Edwards, John E. ;
Calandra, Thierry ;
Pappas, Peter G. ;
Maertens, Johan ;
Lortholary, Olivier ;
Kauffman, Carol A. ;
Denning, David W. ;
Patterson, Thomas F. ;
Maschmeyer, Georg ;
Bille, Jacques ;
Dismukes, William E. ;
Herbrecht, Raoul ;
Hope, William W. ;
Kibbler, Christopher C. ;
Kullberg, Bart Jan ;
Marr, Kieren A. ;
Munoz, Patricia ;
Odds, Frank C. ;
Perfect, John R. ;
Restrepo, Angela ;
Ruhnke, Markus ;
Segal, Brahm H. ;
Sobel, Jack D. ;
Sorrell, Tania C. ;
Viscoli, Claudio ;
Wingard, John R. ;
Zaoutis, Theoklis ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821